How the complex cellular metabolism of nonsterol mevalonate products influences this control and whether there are compensating mechanisms that suppress an SPP KO phenotype, as well as how an SPP upregulation observed in cancer cells (35, 36) impacts this mechanism, remain to be interesting questions for future research. This evidence concerns the gene HM13 and cancer.